A new "liquid biopsy" test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, while helping some avoid further tests and treatments, including chemotherapy.
Two abstracts on liquid biopsy tests revealed the potential of analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in promoting heightened decision-making by clinicians for ...
Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space ...
Please provide your email address to receive an email when new articles are posted on . Researchers at Johns Hopkins Sidney Kimmel Cancer Center have developed an automated liquid biopsy test that can ...
PALO ALTO, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s ...
Guardant Reveal™ is industry’s first blood-only test able to detect, with 7-day turnaround time, residual disease after surgery and recurrence months earlier than current standard-of-care methods ...
The trial of Theranos CEO Elizabeth Holmes for defrauding investors about the company’s blood tests highlights a more general reality: huge sums of money are being devoted to develop and promote ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results